Free Trial
NASDAQ:GNLX

Genelux 3/29/2024 Earnings Report

Genelux logo
$2.47 -0.16 (-6.05%)
As of 09:40 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genelux EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.21
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genelux Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genelux's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Genelux Earnings Headlines

Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Genelux reports FY24 EPS (95c), consensus (88c)
Genelux announces alignment with FDA of approval pathway for Olvi-Vec
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX), a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

View Genelux Profile

More Earnings Resources from MarketBeat